WST trades 0.9% below Wall Street's consensus target of $330.83.
Last 12 months price action with 12-month analyst target path
The base valuation assumes WST achieves its forward estimates and maintains a stable P/E multiple of 38.1x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, West Pharmaceutical Services, Inc. (WST) has a Wall Street consensus price target of $330.83, based on estimates from 15 covering analysts. With the stock currently trading at $328.03, this represents a potential upside of +0.9%. The company has a market capitalization of $23.64B.
Analyst price targets range from a low of $295.00 to a high of $400.00, representing a 32% spread in expectations. The median target of $317.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, WST trades at a trailing P/E of 48.2x and forward P/E of 38.1x. The forward PEG ratio of 4.60 reflects a premium valuation. Analysts expect EPS to grow +14.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $403.63, with bear and bull scenarios of $254.29 and $531.82 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ATRAptarGroup, Inc. | $7.7B | $120.32 | $188.00 | +56.3% | Buy | 21.8x | 18 |
GTLSChart Industries, Inc. | $10.0B | $207.99 | $193.81 | -6.8% | Buy | 29.9x | 37 |
AVTRAvantor, Inc. | $6.5B | $9.58 | $9.17 | -4.3% | Hold | 12.2x | 26 |
AMCRAmcor plc | $19.0B | $41.08 | $47.75 | +16.2% | Buy | 10.3x | 13 |
SEESealed Air Corporation | $6.2B | $42.15 | $49.92 | +18.4% | Buy | 12.4x | 27 |
PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
MRKMerck & Co., Inc. | $281.2B | $113.87 | $131.58 | +15.6% | Buy | 22.2x | 37 |
ABBVAbbVie Inc. | $383.2B | $216.63 | $256.92 | +18.6% | Buy | 15.2x | 41 |
BDXBecton, Dickinson and Company | $52.2B | $143.98 | $174.81 | +21.4% | Hold | 11.4x | 34 |
Quick answers to the most common questions about buying WST stock.
The consensus price target for WST is $330.83, close to the current price of $328.03 (0.9% implied move). Based on 15 analyst estimates, the stock appears fairly valued near current levels.
WST has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $330.83 implies 0.9% upside from current levels.
At a forward P/E of 38.0912x, WST trades at a premium valuation. The consensus price target of $330.83 (0.9% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $400 for WST, while the most conservative target is $295. The consensus of $330.83 represents the median expectation. Our quantitative valuation model projects a bull case target of $532 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
WST is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month WST stock forecast based on 15 Wall Street analysts shows a consensus price target of $330.83, with estimates ranging from $295 (bear case) to $400 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $404, with bear/bull scenarios of $254/$532.
Our quantitative valuation model calculates WST's fair value at $404 (base case), with a bear case of $254 and bull case of $532. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
WST trades at a forward P/E ratio of 38.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 48.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
WST appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $330.83 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
WST analyst price targets range from $295 to $400, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $330.83 consensus represents the middle ground. Our model's $254-$532 range provides an independent fundamental perspective.
Deep dive into WST consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.